NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.

Shares of Moderna MRNA declined nearly 8% yesterday after it announced that it had voluntarily withdrawn a regulatory filing seeking the FDA’s approval for mRNA-1083, its investigational mRNA ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions.

The Food and Drug Administration gave Covid vaccine manufacturers instructions on what next fall’s Covid vaccines should target on Thursday, signaling it would prefer that they update the strain ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness ...

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.

Nation World FDA approves Novavax COVID-19 shot but with unusual restrictions Novavax makes the nation's only traditional protein-based coronavirus vaccine.